Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist’s Decision on Systemic Therapy in a Real-World Setting

In intermediate risk hormone receptor (HR) positive, HER2 negative breast cancer (BC), the decision regarding adjuvant chemotherapy might be facilitated by multigene expression tests. In all, 142 intermediate risk BCs were investigated using the PAM50-based multigene expression test Prosigna® in a p...

Descripción completa

Detalles Bibliográficos
Autores principales: Erber, Ramona, Angeloni, Miriam, Stöhr, Robert, Lux, Michael P., Ulbrich-Gebauer, Daniel, Pelz, Enrico, Bankfalvi, Agnes, Schmid, Kurt W., Walter, Robert F. H., Vetter, Martina, Thomssen, Christoph, Mayr, Doris, Klauschen, Frederick, Sinn, Peter, Sotlar, Karl, Stering, Katharina, Stenzinger, Albrecht, Wunderle, Marius, Fasching, Peter A., Beckmann, Matthias W., Hoffmann, Oliver, Kimmig, Rainer, Harbeck, Nadia, Wuerstlein, Rachel, Ferrazzi, Fulvia, Hartmann, Arndt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9368794/
https://www.ncbi.nlm.nih.gov/pubmed/35955851
http://dx.doi.org/10.3390/ijms23158716

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9368794/
https://www.ncbi.nlm.nih.gov/pubmed/35955851
http://dx.doi.org/10.3390/ijms23158716

Ejemplares similares